Program
olsutamig
Also written as “REGN15505+REGN4336” and “REGN4336”.
Its studies are mostly in Carcinoma, Renal Cell · Prostatic Neoplasms, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since Oct 25, 20212 company-led studies, 2 open or runningNext primary completion: Mar 28, 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 22 open or running | phase 2since Oct 25, 2021 | Oct 25, 2021 | Mar 28, 2030phase 2 · NCT05125016 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 25, 2021First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT05125016 · 228 planned · United States
- May 11, 2026Phase 2 study in Carcinoma, Renal CellNCT07594106 · 265 planned · United States
Ahead
- Mar 28, 2030Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT05125016
- Oct 27, 2030Primary completion: phase 2 study in Carcinoma, Renal CellNCT07594106
TargetBeta
“A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514rule | GlaxoSmithKline | phase 2 | 1 |
| Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rule | janux-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07594106Carcinoma, Renal Cell · United States | 2 | Recruiting | Oct 27, 2030 | 265 |
| NCT05125016Metastatic Castration-resistant Prostate Cancer · United States | 2 | Recruiting | Mar 28, 2030 | 228 |
How it is read
Names in the registry
- “REGN15505+REGN4336”, 1 entry
- “REGN4336”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.